Phase 3 Trial Reveals Promising Results for LS-SCLC Patients
A groundbreaking study presented at the 2023 ASTRO Annual Meeting has unveiled a potential game-changer in the treatment of limited-stage small cell lung cancer (LS-SCLC). The study highlights the efficacy of high-dose hyperfractionated thoracic radiotherapy in improving patient outcomes.
HCN Medical Memo
This study underscores the potential of high-dose hyperfractionated thoracic radiotherapy as an alternative treatment option for LS-SCLC. Healthcare professionals can leverage this information to explore new treatment avenues and improve patient care.
- The phase 3 trial was conducted in China, with patients randomly assigned to receive either high-dose or standard-dose thoracic volumetric modulated arc radiotherapy (VMAT) along with chemotherapy.
- The median overall survival was 62.4 months in the hyperfractionated arm and 43.1 months in the standard arm.
- The median progression-free survival (PFS) was 30.5 months in the hyperfractionated arm and 16.7 months in the standard arm.
- Adverse events were similar between the treatment arms.
Small cell lung cancer accounts for about 10-15% of all lung cancers.
More on Small-Cell Lung Cancer